MAPT and Alzheimer disease: Nowadays, the diagnosis of AD is based on clinical examination supported by the detection of Aβ, phosphorylated (p-tau), and total tau (t-tau) protein levels in the cerebrospinal fluid (CSF) of patients in combination with advanced neuroimaging techniques such as positron emission tomography (PET) and volumetric magnetic resonance imaging (MRI) [15].